-
Fosun Pharma Partners with Soong Ching Ling Foundation for Women and Children’s Health
•
The 5th China International Import Expo (CIIE) saw Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announce a partnership with the Shanghai Soong Ching Ling Foundation. The collaboration aims to carry out medical and health public welfare activities for women and children, with Xishuangbanna of Yunnan province as the primary…
-
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
•
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co., Ltd to develop and commercialize two target products in mainland China. The collaboration involves a PDE4 inhibitor (target product one) and a protease inhibitor (target product two). Jumpcan will pay RMB 180 million (USD 24.8…
-
Novo Nordisk to Invest RMB 400M in Shanghai at CIIE
•
Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an investment of RMB 400 million (USD 55.2 million) to establish an investment unit in Shanghai. The new unit is designed to maintain ownership of its manufacturing, trade, research and development (R&D), and other business operations…
-
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the enrollment of the first subject in a prospective, subject-controlled, multi-center Phase III clinical study. The study aims to assess the additional detection rate and safety of Hexvix, a bladder cancer diagnosis and postoperative detection product,…
-
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category 1 drug candidate BPI-452080 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of the drug, which is designed to treat advanced solid…
-
Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study
•
China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase I study. The study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of its RGT-264 phosphate tablets in patients with advanced solid tumors. RGT-264 ProfileRGT-264 is a…
-
Hainan Free Trade Port to Simplify Drug Import Procedures
•
The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September this year, will take effect as of December 1, 2022. These new regulations aim to streamline the import process for pharmaceuticals, enhancing efficiency and reducing administrative burdens. Regulatory ChangesThe Provisions specify that enterprises importing drugs…
-
Hainan Free Trade Port to Simplify Drug Import Procedures
•
The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September this year, will take effect as of December 1, 2022. These new regulations aim to streamline the import process for pharmaceuticals, enhancing efficiency and reducing administrative burdens. Regulatory ChangesThe Provisions specify that enterprises importing drugs…
